Major Accomplishments

When SAA was founded in 1983, there was no support network, no resource for educational materials, not even a single pamphlet for people with spondylitis. Today, SAA produces the best informational materials on worldwide developments in spondylitis treatment and research. SAA's network of supportive programs ensure that those affected by spondylitis do not have to face this disease alone. Regardless of location, individuals and their families can find the tools they need and connect with someone who listens and understands.


Phase I of the Spondylitis Association of America’s patient registry, which includes 10 years of data for analysis, is completed. By combining existing patient databases used in research, the composite database can be used to look at potentially tens of thousands of patients and track health trends, disease severity over time, age, gender, race, and many other factors to improve understanding of the disease.

The Spondylitis Association of America (SAA) is again awarded a 4-star rating from Charity Navigator for excellence in fiscal responsibility and transparency.


SAA funds research by Medical Board member James T. Rosenbaum, MD to test his hypothesis that HLA-B27 shapes the gut microbiome. Alteration of the microbiome potentially could be used to treat or prevent many diseases caused by the immune system including ankylosing spondylitis.


The culmination of years of work by the SAA, the American College of Rheumatology (ACR), and Spondyloarthritis Research and Treatment Network (SPARTAN), “The Axial SpA Treatment Guidelines” are presented at the American College of Rheumatology Scientific Meeting. These guidelines bring together cohesive treatment recommendations to be considered by U.S. rheumatologists in treating people diagnosed with the disease.

SAA holds a state-of-the-art certified continuing medical education (CME) program called "Magnetic Imaging Workshop in Spondyloarthritis (SpA.)" The purpose of this CME program was to teach radiologists and rheumatologists to recognize early inflammatory changes in bone marrow and soft tissue at symptom onset, leading to earlier and more accurate diagnoses.

SAA funds research by Medical Board member Joel Taurog, MD into the molecular basis for the association of ankylosing spondylitis with HLA-B27.

SAA is again awarded a 4-star rating from Charity Navigator for excellence in fiscal responsibility and transparency.


SAA establishes its annual Young Investigator Award (later renamed the SAA/Bruckel Early Career Investigator Award) which recognizes outstanding "contributions to the care and understanding of patients with spondyloarthritis." The award winner gets a $10,000 grant from SAA for use in research in the field of spondylitis.

The first ever U.S. epidemiology study data, compiled by the Centers for Disease Control and Prevention (CDC) and supported by SAA and SPARTAN is released. The CDC researchers used the data and statistical methodology from SAA’s Screening Tool for Ankylosing Spondylitis as a foundation for the patient questionnaire they developed for the 2009/2010 National Health and Nutrition Examination Survey (NHANES).

SAA is again awarded a 4-star rating from Charity Navigator for excellence in fiscal responsibility and transparency.


SAA launches the second "Ankylosing Spondylitis (AS) Life Impact Study" to poll those affected about onset of symptoms, diagnosis, treatments, medications, and quality of life issues.

The Triple “A” Ankylosing Spondyloarthritis Consortium (TASC) genetic study identifies three variants in the RUNX3, LTBR-TNFRSF1A, and IL12B regions of the human genome that are convincingly associated with ankylosing spondylitis, as well as four additional areas that also seem to play a role—PTGER4, TBKBP1, KIF21B, and CARD9. Other genetic suspects include CDKALI, TRADD, and STAT3.


SAA completes the first-ever training video for emergency first responders, titled "Ankylosing Spondylitis: Managing Patients in an Emergency Setting, A Primer for First Responders." The program is accredited by the Continuing Education Coordinating Board for Emergency Medical Services (CECBEMS), meaning that first responders can receive continuing education credit for this training. The program is adopted by hundreds of fire chiefs in the United States and by several states, including Florida, which makes it part of the mandatory training curricula for first responders.

The validated study manuscript for "The SAA Screening Tool for Ankylosing Spondylitis” is accepted for publication by Arthritis and Research. SAA launches to disseminate the online screening tool.


Laurie M. Savage assumes the role of Executive Director of SAA, having served for nine years as Director of Programs and three as Associate Director.

The SAA oversees recruitment of patients and families for the TASC genetic study, which identifies two additional genes—ERAP1 and IL23R—that play a role in susceptibility to spondylitis. This is hailed as the most significant breakthrough in spondylitis research since the association of HLA-B27 with ankylosing spondylitis was discovered in 1972.

SAA contributes to the effort to bring about the Genetic Information Non-Discrimination Act (GINA), which is signed into law.


SAA co-sponsors a second scientific conference with the NIH, titled "Spondyloarthritis: The Unmet Needs." The purpose of the meeting, organized by John D. Reveille, MD and Laurie M. Savage, is to bring together experts in several different scientific areas to foster multidisciplinary approaches to the classification, pathogenesis and management of AS and its related diseases. 

The NIH awards an additional grant in the amount of $5 million to the genetic project headed by John D. Reveille, MD, with a goal of identifying the exact genes within the seven chromosome regions that cause and influence ankylosing spondylitis.

Jane Bruckel retires from her role as Executive Director after 23 years at the helm of the organization. The position is filled in the interim until Laurie Savage takes the lead position in 2008.


SAA begins a second major research project, "The Development of an Online Screening Tool to Identify People at Risk for AS," with Michael H. Weisman, MD as Principal Investigator.


SAA holds an organizational meeting for U.S. researchers to establish the Spondyloarthritis Research and Treatment Network for the purpose of advancing clinical research of spondyloarthritis in the United States.

SAA offers its first accredited continuing medical education (CME) program for physicians titled, "Ankylosing Spondylitis and& Related Spondyloarthropathies: Aggressive Management of Aggressive Diseases."

Jane Bruckel testifies before the Food and Drug Administration (FDA) to advocate for approval of Enbrel as the first biologic drug for ankylosing spondylitis.


SAA sponsors and develops the first extensive survey among AS patients nationwide. “The AS Life Impact Survey” results in major findings never before documented that enable physicians and SAA to better address the needs of the AS community.

SAA helps organize a meeting with European research group Assessment of SpondyloArthritis international Society (ASAS), the FDA, researchers, and pharmaceutical companies to draft an FDA guidance document on AS drug research and development.


SAA and the University of Texas (UT) form the North American Spondylitis Consortium (NASC), a consortium of 10 university medical centers and SAA. The NIH provides a $6.5 million grant and designates SAA as clinical coordinating center for the AS Family Genetic Project.


SAA co-sponsors a two-day scientific symposium in cooperation with the NIH. The purpose of the meeting is to encourage a dialogue between research clinicians in spondyloarthritis and those in the bone and gut fields.

SAA provides the seed money for John D. Reveille, MD and Li Jin, MD, both of the University of Houston to begin the first major, nationwide genetic study of ankylosing spondylitis.


SAA's Board of Directors change the organization's major focus to funding and helping to organize research efforts.

Jane Bruckel meets with National Institutes of Health Director Stephen Katz to announce SAA's new research commitment and discuss future collaborations.

SAA embarks on fundraising for AS research with the leading gift of $30,000 from The Jean and E. Floyd Kvamme Foundation and Damon Kvamme.


The organization changes its name to the Spondylitis Association of America (SAA), in order to reflect a broadened mission that encompasses diseases related to ankylosing spondylitis.


ASA establishes a national Medical & Scientific Advisory Board, comprised of distinguished spondylitis researchers and health professionals.

Jane Bruckel becomes ASA's first Executive Director.


The organization first appears on the public radar when the Los Angeles Times runs an article titled, "The Back Pain with the Funny Name". The article results in more than 500 letters and phone calls, creating a surge in membership from across the country.

ASA produces the first comprehensive patient self-management book, “Straight Talk on Spondylitis,” which receives high praise from medical professionals worldwide. More than 3,000 copies are distributed to patients, physicians and major medical centers. The book is translated into Japanese and distributed throughout Japan. The English version was updated in 1992 and completely edited and brought current in 2009.


The organization becomes a tax-exempt, nonprofit corporation under the name Ankylosing Spondylitis Association (ASA). Volunteer, nurse and spondylitis patient Jane Bruckel was elected the group's first president.

The group co-sponsors the first AS symposium in the U.S. More than 100 physicians attend the first day of the program, titled "Back Pain: The Unsuspected Cause." The second day, over 100 patients attend a program titled "AS: A Cause of Back Pain. What it is, what it is not, and how to cope with it."


The organization today known as the Spondylitis Association of America holds its first meeting in Los Angeles, where ten patients and two physicians create the country's first-ever ankylosing spondylitis (AS) support group.

The organization produces the first quarterly newsletter specifically written for spondylitis patients.

For more than 30 years, the Spondylitis Association of America has spoken out on behalf of all who suffer from spondylitis. By making a donation to SAA, you will directly contribute to much-needed public awareness efforts, educational outreach programs, research initiatives, treatment advances and the ongoing search for the cure. Add your voice to our mission to be a leader in the quest to cure ankylosing spondylitis and related diseases and to empower those affected to live life to the fullest. Together, our voice is louder. Together, we make a difference.

Contribute Now